Phentermine Clinical Trials

Browse current and past clinical studies and trials involving the prescription weight loss drug phentermine hydrochloride.

Currently Active Clinical Trials Involving Phentermine (United States)

Title	Status	Study Results	Conditions_raw	Conditions	Interventions_raw	Interventions	Locations_raw	Locations	Study Details
Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity	Recruiting	No Results Available	Obesity	Obesity	Drug: Phentermine 37.5 Mg\|Behavioral: Dietary program\|Behavioral: Exercise program	Drug: Phentermine 37.5 Mg Behavioral: Dietary program Behavioral: Exercise program	Cleveland Clinic, Cleveland, Ohio, United States	Cleveland Clinic, Cleveland, Ohio, United States
Pharmacotherapy for Pediatric Obesity: A Phentermine Clinical Trial	Not yet recruiting	No Results Available	Obesity, Childhood	Obesity, Childhood	Drug: Lifestyle Management	Drug: Lifestyle Management	University of Minnesota, Saint Paul, MN (asdf)	University of Minnesota, Saint Paul, MN (asdf)
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds	Recruiting	No Results Available	Obesity, Morbid\|Bariatric Surgery\|Adolescent\|Young Adult\|Drug Therapy	Obesity, Morbid Bariatric Surgery Adolescent Young Adult Drug Therapy	Drug: Phentermine\|Drug: Immediate Release Topiramate\|Drug: Placebo for Phentermine\|Drug: Placebo for Immediate Release Topiramate	Drug: Phentermine Drug: Immediate Release Topiramate Drug: Placebo for Phentermine Drug: Placebo for Immediate Release Topiramate	Children's Hospital Colorado, Aurora, Colorado, United States	Children's Hospital Colorado, Aurora, Colorado, United States
Obesity and Uric Acid Stones Study	Recruiting	No Results Available	Obesity\|Uric Acid Stones\|Type 2 Diabetes Mellitus in Obese\|Pre-Diabetes	Obesity Uric Acid Stones Type 2 Diabetes Mellitus in Obese Pre-Diabetes	Drug: Phentermine / Topiramate Oral Product\|Combination Product: Citrate Salts, Allopurinol, Diet	Drug: Phentermine / Topiramate Oral Product Combination Product: Citrate Salts, Allopurinol, Diet	University of Florida, Gainesville, Florida, United States	University of Florida, Gainesville, Florida, United States
Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker	Recruiting	No Results Available	Obesity	Obesity	Drug: Phentermine-Topiramate Extended Release\|Drug: Placebo\|Other: Online support system	Drug: Phentermine-Topiramate Extended Release Drug: Placebo Other: Online support system	Mayo Clinic in Rochester, Rochester, Minnesota, United States	Mayo Clinic in Rochester, Rochester, Minnesota, United States
Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity	Not yet recruiting	No Results Available	Obesity	Obesity	Drug: Phentermine-Topiramate\|Dietary Supplement: Meal Replacement Therapy\|Other: Placebo	Drug: Phentermine-Topiramate Dietary Supplement: Meal Replacement Therapy Other: Placebo	University of Minnesota, Minneapolis, Minnesota, United States	University of Minnesota, Minneapolis, Minnesota, United States
A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents	Active, not recruiting	No Results Available	Adolescent Obesity\|Obesity in Adolescence\|Adolescent Overweight	Adolescent Obesity Obesity in Adolescence Adolescent Overweight	Drug: VI-0521 oral capsule\|Drug: Placebo oral capsule	Drug: VI-0521 oral capsule Drug: Placebo oral capsule	Intend Research, LLC, Norman, Oklahoma, United States	Intend Research, LLC, Norman, Oklahoma, United States
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients	Recruiting	No Results Available	Colitis, Ulcerative\|Obesity	Colitis, Ulcerative Obesity	Drug: Phentermine-Topiramate\|Drug: Placebo	Drug: Phentermine-Topiramate Drug: Placebo	University of California San Diego, La Jolla, California, United States	University of California San Diego, La Jolla, California, United States
Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment	Recruiting	No Results Available	Obesity	Obesity	Behavioral: Behavioral Treatment\|Drug: Placebo\|Drug: Phentermine 15 MG	Behavioral: Behavioral Treatment Drug: Placebo Drug: Phentermine 15 MG	University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States	University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States
SMART Use of Medication for the Treatment of Adolescent Severe Obesity	Recruiting	No Results Available	Adolescent Obesity	Adolescent Obesity	Behavioral: Lifestyle Modification Therapy (LSMT)\|Drug: Phentermine Pill\|Drug: Topiramate Pill	Behavioral: Lifestyle Modification Therapy (LSMT) Drug: Phentermine Pill Drug: Topiramate Pill	University of Minnesota, Minneapolis, Minnesota, United States	University of Minnesota, Minneapolis, Minnesota, United States
Medications After Adolescent Bariatric Surgery	Not yet recruiting	No Results Available	Pediatric Obesity	Pediatric Obesity	Drug: Topiramate\|Drug: Phentermine	Drug: Topiramate Drug: Phentermine	Stanford University, Palo Alto, California, United States	Stanford University, Palo Alto, California, United States
Individualized Obesity Pharmacotherapy	Recruiting	No Results Available	Obesity	Obesity	Drug: Phentermine-Topiramate\|Drug: Liraglutide\|Drug: Naltrexone/bupropion\|Drug: Phentermine	Drug: Phentermine-Topiramate Drug: Liraglutide Drug: Naltrexone/bupropion Drug: Phentermine	Mayo Clinic in Rochester, Rochester, Minnesota, United States	Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate	Recruiting	No Results Available	Healthy Volunteers	Healthy Volunteers	Drug: Propranolol 160 mg\|Drug: Pindolol 20 mg\|Drug: Dantrolene 100 mg\|Drug: Magnesium Sulfate\|Drug: Caffeine 200 mg\|Drug: Qsymia (topiramate 92 mg CR,phentermine 15 mgPO)\|Drug: Topiramate 200 mg\|Drug: Phentermine 37.5 mg\|Behavioral: Naltrexone 100 mg\|Drug: Mirabegron 50 mg\|Drug: Mirabgron 200 mg\|Other: Placebo	Drug: Propranolol 160 mg Drug: Pindolol 20 mg Drug: Dantrolene 100 mg Drug: Magnesium Sulfate Drug: Caffeine 200 mg Drug: Qsymia (topiramate 92 mg CR,phentermine 15 mgPO) Drug: Topiramate 200 mg Drug: Phentermine 37.5 mg Behavioral: Naltrexone 100 mg Drug: Mirabegron 50 mg Drug: Mirabgron 200 mg Other: Placebo	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States	National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial	Recruiting	No Results Available	Type 2 Diabetes\|Obesity	Type 2 Diabetes Obesity	Other: Weight Management Program (WMP)\|Other: Traditional care\|Drug: Phentermine / Topiramate Extended Release Oral Capsule\|Drug: naltrexone/bupropion extended-release\|Drug: liraglutide 3.0 mg\|Drug: Orlistat	Other: Weight Management Program (WMP) Other: Traditional care Drug: Phentermine / Topiramate Extended Release Oral Capsule Drug: naltrexone/bupropion extended-release Drug: liraglutide 3.0 mg Drug: Orlistat	Cleveland Clinic, Cleveland, Ohio, United States	Cleveland Clinic, Cleveland, Ohio, United States
Title	Status	Study Results	Conditions_raw	Conditions	Interventions_raw	Interventions	Locations_raw	Locations	Study Details

Inactive/Completed Clinical Trials Involving Phentermine (United States)

Title	Status	Study Results	Conditions_raw	Conditions	Interventions_raw	Interventions	Locations_raw	Locations
The Effect of Phentermine and B12 on Weight Loss Among Obese Patients	Completed	No Results Available	Obesity\|Hypertension	Obesity Hypertension	Drug: Phentermine and B12\|Drug: Phentermine	Drug: Phentermine and B12 Drug: Phentermine	Brody Outpatient of Brody Medical Sciences Module D, Greenville, North Carolina, United States	Brody Outpatient of Brody Medical Sciences Module D, Greenville, North Carolina, United States
Studying the Effects of Phentermine on Eating Behavior	Completed	Has Results	Obesity	Obesity	Drug: Phentermine\|Drug: placebo	Drug: Phentermine Drug: placebo	The New York State Psychiatric Institute at Columbia University Medical Center, New York, New York, United States	The New York State Psychiatric Institute at Columbia University Medical Center, New York, New York, United States
Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients	Completed	Has Results	Obesity	Obesity	Drug: Phentermine-Topiramate ER\|Drug: Placebo	Drug: Phentermine-Topiramate ER Drug: Placebo	Mayo Clinic in Rochester, Rochester, Minnesota, United States	Mayo Clinic in Rochester, Rochester, Minnesota, United States
Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal	Completed	No Results Available	Obesity\|Phentermine Withdrawal	Obesity Phentermine Withdrawal	Drug: Abrupt cessation of phentermine pharmacotherapy	Drug: Abrupt cessation of phentermine pharmacotherapy	Center for Weight Management, Roseville, California, United States\|Center for Weight Management, Sacramento, California, United States	Center for Weight Management, Roseville, California, United States Center for Weight Management, Sacramento, California, United States
Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity	Withdrawn	No Results Available	Obesity\|Diabetes Mellitus	Obesity Diabetes Mellitus	Other: Behavioral and Drug\|Other: Behavioral	Other: Behavioral and Drug Other: Behavioral	Captain James A. Lovell Federal Health Care Center, North Chicago, IL, North Chicago, Illinois, United States	Captain James A. Lovell Federal Health Care Center, North Chicago, IL, North Chicago, Illinois, United States
Topiramate-Phentermine Combinations for Cocaine Dependence	Completed	No Results Available	Cocaine Use Disorder	Cocaine Use Disorder	Drug: Cocaine\|Drug: Placebo\|Drug: Phentermine\|Drug: Topiramate	Drug: Cocaine Drug: Placebo Drug: Phentermine Drug: Topiramate	University of Kentucky Medical Center, Lexington, Kentucky, United States	University of Kentucky Medical Center, Lexington, Kentucky, United States
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults	Completed	No Results Available	Obesity	Obesity	Drug: topiramate\|Drug: phentermine	Drug: topiramate Drug: phentermine	VIVUS, Inc., Mountain View, California, United States	VIVUS, Inc., Mountain View, California, United States
FDA Approved Medication to Reduce Binge Eating and/or Purging	Completed	No Results Available	Binge Eating Disorder\|Bulimia Nervosa	Binge Eating Disorder Bulimia Nervosa	Drug: Phentermine/Topiramate-First\|Drug: Placebo	Drug: Phentermine/Topiramate-First Drug: Placebo	Stanford School of Medicine, Psychiatry and Behavioral Sciences, Stanford, California, United States	Stanford School of Medicine, Psychiatry and Behavioral Sciences, Stanford, California, United States
A Study to Evaluate Abuse Potential of Istradefylline	Completed	No Results Available	Drug Abuse	Drug Abuse	Drug: Istradefylline\|Drug: Phentermine 45 mg\|Other: Placebo	Drug: Istradefylline Drug: Phentermine 45 mg Other: Placebo	Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States	Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States
Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)	Completed	Has Results	Obesity\|Overweight\|Metabolic Diseases	Obesity Overweight Metabolic Diseases	Behavioral: Low Calorie Diet (LCD)\|Drug: Phentermine	Behavioral: Low Calorie Diet (LCD) Drug: Phentermine	Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States	Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)	Completed	No Results Available	Binge Eating Disorder	Binge Eating Disorder	Drug: PHEN/TPM ER (Qsymia®)	Drug: PHEN/TPM ER (Qsymia®)	Lindner Center of HOPE, Mason, Ohio, United States	Lindner Center of HOPE, Mason, Ohio, United States
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)	Completed	Has Results	Polycystic Ovary Syndrome\|Obesity	Polycystic Ovary Syndrome Obesity	Drug: Exenatide once weekly (EQW )\|Drug: Dapagliflozin (DAPA)\|Drug: EQW plus DAPA\|Drug: Dapagliflozin plus Glucophage (MET ER)\|Drug: Phentermine /Topiramate (PHEN/ TPM) ER	Drug: Exenatide once weekly (EQW ) Drug: Dapagliflozin (DAPA) Drug: EQW plus DAPA Drug: Dapagliflozin plus Glucophage (MET ER) Drug: Phentermine /Topiramate (PHEN/ TPM) ER	Woman's Hospital, Baton Rouge, Louisiana, United States	Woman's Hospital, Baton Rouge, Louisiana, United States
Qsymia as an Adjunct to Surgical Therapy in the Superobese	Completed	Has Results	Obesity\|Metabolic Surgery\|Weight Loss\|Bariatric Surgery Procedures	Obesity Metabolic Surgery Weight Loss Bariatric Surgery Procedures	Drug: Phentermine/topiramate\|Other: low calorie diet	Drug: Phentermine/topiramate Other: low calorie diet	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States	Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.	Completed	No Results Available	Obesity	Obesity	Drug: Metformin, VI-0521, Sitagliptan, Probenecid	Drug: Metformin, VI-0521, Sitagliptan, Probenecid	MDS Pharma Services, Phoenix, Arizona, United States	MDS Pharma Services, Phoenix, Arizona, United States
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults	Completed	Has Results	Obesity	Obesity	Drug: VI-0521\|Drug: topiramate\|Drug: phentermine	Drug: VI-0521 Drug: topiramate Drug: phentermine	Research Site, Durham, North Carolina, United States\|Research Site, Philadelphia, Pennsylvania, United States	Research Site, Durham, North Carolina, United States Research Site, Philadelphia, Pennsylvania, United States
A Toolbox Approach to Obesity Treatment in Primary Care	Completed	Has Results	Obesity	Obesity	Behavioral: Commercial weight loss program\|Behavioral: Colorado Weigh\|Dietary Supplement: Meal replacements\|Drug: Obesity pharmacotherapy\|Behavioral: Recreation center passes	Behavioral: Commercial weight loss program Behavioral: Colorado Weigh Dietary Supplement: Meal replacements Drug: Obesity pharmacotherapy Behavioral: Recreation center passes	Denver Health and Hospital Authority, Denver, Colorado, United States	Denver Health and Hospital Authority, Denver, Colorado, United States
A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment	Completed	No Results Available	Renal Impairment	Renal Impairment	Drug: Topirmate and Phentermine	Drug: Topirmate and Phentermine	Advanced Clinical Research Institute, Anaheim, California, United States\|Clinical Pharmacology of Miami, Miami, Florida, United States\|Orlando Clinical Research Center, Orlando, Florida, United States\|DaVita Clinical Research, Minneapolis, Minnesota, United States	Advanced Clinical Research Institute, Anaheim, California, United States Clinical Pharmacology of Miami, Miami, Florida, United States Orlando Clinical Research Center, Orlando, Florida, United States DaVita Clinical Research, Minneapolis, Minnesota, United States
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment	Completed	No Results Available	Hepatic Impairment	Hepatic Impairment	Drug: Phentermine and Topiramate	Drug: Phentermine and Topiramate	Clinical Pharmacology of Miami, Miami, Florida, United States\|Orlando Clinical Research Center, Orlando, Florida, United States	Clinical Pharmacology of Miami, Miami, Florida, United States Orlando Clinical Research Center, Orlando, Florida, United States
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects	Completed	Has Results	Obesity	Obesity	Drug: Qsymia\|Drug: Placebo	Drug: Qsymia Drug: Placebo	Research Center, Lakewood, Colorado, United States	Research Center, Lakewood, Colorado, United States
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents	Completed	Has Results	Pediatric Obesity\|Childhood Obesity	Pediatric Obesity Childhood Obesity	Drug: Placebo\|Drug: VI-0521 Mid Dose\|Drug: VI-0521 Top Dose	Drug: Placebo Drug: VI-0521 Mid Dose Drug: VI-0521 Top Dose	Research Facility, Baton Rouge, Louisiana, United States\|Research Facility, Marrero, Louisiana, United States\|Research Facility, Cincinnati, Ohio, United States\|Research Facility, Charleston, South Carolina, United States	Research Facility, Baton Rouge, Louisiana, United States Research Facility, Marrero, Louisiana, United States Research Facility, Cincinnati, Ohio, United States Research Facility, Charleston, South Carolina, United States
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults	Completed	Has Results	Sleep Apnea	Sleep Apnea	Drug: VI-0521\|Drug: placebo	Drug: VI-0521 Drug: placebo	Kentucky Research Group, Louisville, Kentucky, United States	Kentucky Research Group, Louisville, Kentucky, United States
Lifestyle Modification and Liraglutide	Completed	Has Results	Obesity	Obesity	Behavioral: CMS-recommended lifestyle counseling\|Drug: Liraglutide 3.0mg\|Other: Portion-Controlled Diet\|Drug: Placebo Oral Tablet\|Drug: Phentermine 15 MG\|Behavioral: Extension Study CMS-recommended lifestyle counseling	Behavioral: CMS-recommended lifestyle counseling Drug: Liraglutide 3.0mg Other: Portion-Controlled Diet Drug: Placebo Oral Tablet Drug: Phentermine 15 MG Behavioral: Extension Study CMS-recommended lifestyle counseling	University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States	University of Pennsylvania Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity	Completed	Has Results	Obesity	Obesity	Other: Weight Management Program (WMP)\|Drug: Medication for chronic weight management (Rx)	Other: Weight Management Program (WMP) Drug: Medication for chronic weight management (Rx)	Novo Nordisk Investigational Site, Cleveland, Ohio, United States	Novo Nordisk Investigational Site, Cleveland, Ohio, United States
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants	Completed	Has Results	Obesity	Obesity	Drug: Canagliflozin\|Drug: Phentermine\|Drug: Matching Placebo to Canagliflozin\|Drug: Matching Placebo to Phentermine	Drug: Canagliflozin Drug: Phentermine Drug: Matching Placebo to Canagliflozin Drug: Matching Placebo to Phentermine	Phoenix, Arizona, United States\|Walnut Creek, California, United States\|Jacksonville, Florida, United States\|Meridian, Idaho, United States\|Evansville, Indiana, United States\|Lexington, Kentucky, United States\|Louisville, Kentucky, United States\|New Orleans, Louisiana, United States\|Milford, Massachusetts, United States\|Manlius, New York, United States\|Warwick, Rhode Island, United States\|Mt Pleasant, South Carolina, United States\|Nashville, Tennessee, United States\|Dallas, Texas, United States\|Odessa, Texas, United States\|Norfolk, Virginia, United States\|Wauwatosa, Wisconsin, United States	Phoenix, Arizona, United States Walnut Creek, California, United States Jacksonville, Florida, United States Meridian, Idaho, United States Evansville, Indiana, United States Lexington, Kentucky, United States Louisville, Kentucky, United States New Orleans, Louisiana, United States Milford, Massachusetts, United States Manlius, New York, United States Warwick, Rhode Island, United States Mt Pleasant, South Carolina, United States Nashville, Tennessee, United States Dallas, Texas, United States Odessa, Texas, United States Norfolk, Virginia, United States Wauwatosa, Wisconsin, United States
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults	Completed	Has Results	Chronic Weight Management	Chronic Weight Management	Drug: lorcaserin + phentermine placebo\|Drug: lorcaserin + phentermine-HCl + phentermine placebo\|Drug: lorcaserin + phentermine-HCl	Drug: lorcaserin + phentermine placebo Drug: lorcaserin + phentermine-HCl + phentermine placebo Drug: lorcaserin + phentermine-HCl	University of Alabama at Birmingham, Birmingham, Alabama, United States\|Radiant Research - Arizona, Chandler, Arizona, United States\|Scripps Clinical Research Center, La Jolla, California, United States\|Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States\|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States\|Boston Medical Center, Boston, Massachusetts, United States\|Weill Cornell College, New York, New York, United States\|Duke University, Durham, North Carolina, United States\|Radiant Research - Columbus, Columbus, Ohio, United States\|Radiant Research - South Carolina, Anderson, South Carolina, United States\|Radiant Research - Dallas, Dallas, Texas, United States\|National Clinical Research - Norfolk, Norfolk, Virginia, United States\|National Clinical Research - Richmond, Richmond, Virginia, United States	University of Alabama at Birmingham, Birmingham, Alabama, United States Radiant Research - Arizona, Chandler, Arizona, United States Scripps Clinical Research Center, La Jolla, California, United States Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States Boston Medical Center, Boston, Massachusetts, United States Weill Cornell College, New York, New York, United States Duke University, Durham, North Carolina, United States Radiant Research - Columbus, Columbus, Ohio, United States Radiant Research - South Carolina, Anderson, South Carolina, United States Radiant Research - Dallas, Dallas, Texas, United States National Clinical Research - Norfolk, Norfolk, Virginia, United States National Clinical Research - Richmond, Richmond, Virginia, United States
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults	Completed	Has Results	Obesity	Obesity	Drug: VI-0521\|Drug: Placebo matched phentermine/topiramate	Drug: VI-0521 Drug: Placebo matched phentermine/topiramate	Research Site, San Diego, California, United States\|Research, Ridgefield, Connecticut, United States\|Research Site, Durham, North Carolina, United States\|Research Site, Toledo, Ohio, United States\|Research Site, Austin, Texas, United States	Research Site, San Diego, California, United States Research, Ridgefield, Connecticut, United States Research Site, Durham, North Carolina, United States Research Site, Toledo, Ohio, United States Research Site, Austin, Texas, United States
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects	Completed	No Results Available	Overweight\|Obesity	Overweight Obesity	Drug: pramlintide acetate\|Drug: sibutramine\|Drug: phentermine\|Drug: placebo	Drug: pramlintide acetate Drug: sibutramine Drug: phentermine Drug: placebo	Research Site, Birmingham, Alabama, United States\|Research Site, Phoenix, Arizona, United States\|Research Site, Chula Vista, California, United States\|Research Site, La Jolla, California, United States\|Research Site, Los Angeles, California, United States\|Research Site, Walnut Creek, California, United States\|Research Site, Miami, Florida, United States\|Research Site, Pembroke Pines, Florida, United States\|Research Site, Louisville, Kentucky, United States\|Research Site, New York, New York, United States\|Research Site, Raleigh, North Carolina, United States\|Research Site, Statesville, North Carolina, United States\|Research Site, Eugene, Oregon, United States\|Research Site, Philadelphia, Pennsylvania, United States\|Research Site, Austin, Texas, United States\|Research Site, San Antonio, Texas, United States	Research Site, Birmingham, Alabama, United States Research Site, Phoenix, Arizona, United States Research Site, Chula Vista, California, United States Research Site, La Jolla, California, United States Research Site, Los Angeles, California, United States Research Site, Walnut Creek, California, United States Research Site, Miami, Florida, United States Research Site, Pembroke Pines, Florida, United States Research Site, Louisville, Kentucky, United States Research Site, New York, New York, United States Research Site, Raleigh, North Carolina, United States Research Site, Statesville, North Carolina, United States Research Site, Eugene, Oregon, United States Research Site, Philadelphia, Pennsylvania, United States Research Site, Austin, Texas, United States Research Site, San Antonio, Texas, United States
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults	Completed	Has Results	Diabetes	Diabetes	Drug: Phentermine/Topiramate\|Drug: Placebo	Drug: Phentermine/Topiramate Drug: Placebo	Research Site, Birmingham, Alabama, United States\|Research Site, Los Angeles, California, United States\|Research Site, San Francisco, California, United States\|Research Site, Spring Valley, California, United States\|Research Site, Walnut Creek, California, United States\|Research Site, Bethesda, Maryland, United States\|Research Site, Austin, Texas, United States\|Research Site, San Antonio, Texas, United States\|Research Site, Richmond, Virginia, United States	Research Site, Birmingham, Alabama, United States Research Site, Los Angeles, California, United States Research Site, San Francisco, California, United States Research Site, Spring Valley, California, United States Research Site, Walnut Creek, California, United States Research Site, Bethesda, Maryland, United States Research Site, Austin, Texas, United States Research Site, San Antonio, Texas, United States Research Site, Richmond, Virginia, United States
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.	Completed	Has Results	Overweight\|Obesity	Overweight Obesity	Drug: VI-0521\|Drug: Placebo\|Other: Alcohol\|Other: alcohol placebo	Drug: VI-0521 Drug: Placebo Other: Alcohol Other: alcohol placebo	Research Site, Lincoln, Nebraska, United States	Research Site, Lincoln, Nebraska, United States
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults	Terminated	Has Results	Diabetes	Diabetes	Drug: VI-0521	Drug: VI-0521	Research Site, Birmingham, Alabama, United States\|Research Site, Los Angeles, California, United States\|Research Site, San Francisco, California, United States\|Research Site, Spring Valley, California, United States\|Research Site, Walnut Creek, California, United States\|Research Site, Bethesda, Maryland, United States\|Research Site, Austin, Texas, United States\|Research Site, San Antonio, Texas, United States\|Research Site, Richmond, Virginia, United States	Research Site, Birmingham, Alabama, United States Research Site, Los Angeles, California, United States Research Site, San Francisco, California, United States Research Site, Spring Valley, California, United States Research Site, Walnut Creek, California, United States Research Site, Bethesda, Maryland, United States Research Site, Austin, Texas, United States Research Site, San Antonio, Texas, United States Research Site, Richmond, Virginia, United States
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics	Completed	Has Results	Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Drug: VI-0521\|Drug: Placebo	Drug: VI-0521 Drug: Placebo	Research Site, Birmingham, Alabama, United States\|Research Site, Los Angeles, California, United States\|Research Site, San Francisco, California, United States\|Research Site, Spring Valley, California, United States\|Research Site, Walnut Creek, California, United States\|Research Site, Bethesda, Maryland, United States\|Research Site, Austin, Texas, United States\|Research Site, San Antonio, Texas, United States\|Research Site, Richmond, Virginia, United States	Research Site, Birmingham, Alabama, United States Research Site, Los Angeles, California, United States Research Site, San Francisco, California, United States Research Site, Spring Valley, California, United States Research Site, Walnut Creek, California, United States Research Site, Bethesda, Maryland, United States Research Site, Austin, Texas, United States Research Site, San Antonio, Texas, United States Research Site, Richmond, Virginia, United States
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions	Completed	Has Results	Obesity\|Type 2 Diabetes	Obesity Type 2 Diabetes	Drug: VI-0521	Drug: VI-0521	Research Site, Birmingham, Alabama, United States\|Research Site, Ridgefield, Connecticut, United States\|Research Site, New York, New York, United States\|Research Site, Durham, North Carolina, United States\|Research Site, Toledo, Ohio, United States\|Research Site, Austin, Texas, United States	Research Site, Birmingham, Alabama, United States Research Site, Ridgefield, Connecticut, United States Research Site, New York, New York, United States Research Site, Durham, North Carolina, United States Research Site, Toledo, Ohio, United States Research Site, Austin, Texas, United States